Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG Replacement Therapy for Persistent COVID-19 in B-cell Impaired Patients
NCT06159283Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Human normal immunoglobulin G in coronavirus disease 2019 (COVID-19). Started Mar 2024; status: recruiting.
02
Drugs
Human normal immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06159283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159283.